{"id":"paper-or-2026-084046","type":"book","url":"https://diginpl.com/books/paper-or-2026-084046","language":"en","name":"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer","name_en":"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer","name_ne":null,"description":"Oncology Research · Tian Zeng, Qingxi Luo, Li Yang et al. · 2026","headline":"Oncology Research · Tian Zeng, Qingxi Luo, Li Yang et al. · 2026","also_known_as":[],"summary":"","summary_more":[],"facts":[{"key":"authors","label":"Author","values":[{"text":"Tian Zeng"},{"text":"Qingxi Luo"},{"text":"Li Yang"},{"text":"Feifan Hou"},{"text":"Yongqi Zhao"},{"text":"Xueru Liu"},{"text":"Ni Jiang"},{"text":"Juan Zou"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.084046"}},{"key":"published","label":"Published","values":[{"text":"2026","date":"2026"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.084046"}},{"key":"publisher","label":"Publisher","values":[{"text":"Tech Science Press"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.084046"}},{"key":"journal","label":"Journal","values":[{"text":"Oncology Research"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.084046"}},{"key":"doi","label":"DOI","values":[{"text":"10.32604/or.2026.084046","url":"https://doi.org/10.32604/or.2026.084046"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.084046"}}],"office":null,"sections":[],"cited":[],"cited_from":null,"videos":[],"last_reviewed":null,"organizations":[],"same_as":["https://doi.org/10.32604/or.2026.084046"],"faq":[{"q":"Who wrote ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer?","a":"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was written by Tian Zeng, Qingxi Luo, Li Yang, Feifan Hou."},{"q":"When was ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer first published?","a":"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was first published in 2026."}],"related":[],"places_in":[],"nearby":[],"image":null,"sources":[{"label":"Publisher record (DOI, via Crossref)","url":"https://doi.org/10.32604/or.2026.084046","license":null}],"license":null,"attribution":"Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.084046.","cite":"\"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer\". DigiNepal. Last updated 13 November 2026. https://diginpl.com/books/paper-or-2026-084046. Retrieved 14 November 2026.","date_modified":"2026-11-13T08:01:27Z","facts_checked":"2026-11-13","alternates":{"html":"https://diginpl.com/books/paper-or-2026-084046","en":"https://diginpl.com/books/paper-or-2026-084046","ne":null}}